id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10171 R37147 |
Blotière (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Hypospadias | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.44 [0.08;25.32] C excluded (control group) |
0/139 7/2,997 | 7 | 139 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10039 R36255 |
Blotière (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 | Hypospadias | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 2.00 [0.12;32.22] C | 0/139 3,371/1,875,733 | 3,371 | 139 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9074 R31062 |
Tomson (Oxcarbazepine), 2018 | Hypospadias | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.58 [0.03;10.32] C | 0/333 6/2,514 | 6 | 333 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9062 R30937 |
Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 | Hypospadias/genitourinary tract defects | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 7.58 [0.39;149.00] C | 0/7 6/647 | 6 | 7 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 2.01 [0.38;10.55] | 3,383 | 479 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Oxcarbazepine) (Controls unexposed NOS) (Mixed indications; 2: Oxcarbazepine; 3: Oxcarbazepine) (Controls exposed to Lamotrigine, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 10171